EVAX — Evaxion Biotech A/S

Summary of Evaxion Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended 2025 with $23 million in cash, extending the cash runway into the second half of 2027.
• Revenue: Improved due to MSD option exercises and a grant from the Gates Foundation, contributing to a total cash inflow of $32 million throughout the year.
• Net Loss: Reported a net loss of $7.7 million, an improvement compared to the previous year.
• Equity Strengthening: Successfully executed public offerings and utilized an ATM (at-the-market) program to enhance financial flexibility.

2. Strategic Updates and Business Highlights

• Partnerships: Notable collaboration with MSD, which exercised an option for the EVX-B3 program, marking a significant milestone for Evaxion's AI immunology platform.
• R&D Progress: Positive Phase II data for EVX-01, a personalized cancer vaccine, showing a 75% objective response rate and a 25% complete response rate in advanced melanoma patients.
• Pipeline Expansion: Advancements in the infectious disease portfolio, including the development of EVX-B2 for gonorrhea and EVX-04 targeting acute myeloid leukemia (AML).
• AI Immunology Platform: Recognition from the Galien Foundation for advancements in AI applications in human health, and ongoing enhancements to the platform's predictive capabilities.

3. Forward Guidance and Outlook

• 2026 Milestones: Plans to present additional data for EVX-01, submit regulatory applications for EVX-04, and further explore autoimmune disease applications with the AI platform.
• Partnership Discussions: Ongoing discussions with potential partners for various pipeline assets, particularly in oncology and infectious diseases.

4. Bad News, Challenges, or Points of Concern

• Merck's Decision on EVX-B2: Merck chose not to exercise its option for the EVX-B2 candidate, indicating potential challenges in advancing this program.
• Competitive Landscape: The cancer vaccine space has seen increased scrutiny and competition, which may impact partnership opportunities and market positioning.
• Regulatory Risks: As the company prepares for clinical trials, there are inherent risks associated with regulatory approvals and the success of new candidates.

5. Notable Q&A Insights

• CEO Transition: Helen Tayton-Martin emphasized a strong foundation in Evaxion's strategy, with a focus on optimizing high-value assets without a fundamental change in direction.
• Partnering Strategy: Discussions with large-cap pharma are ongoing, with a focus on validating AI platform capabilities to enhance partnership appeal.
• Autoimmune Disease Focus: The company is analyzing prevalent autoimmune diseases for potential applications of its AI immunology platform, with plans to develop therapies based on identified targets.
• Durability of EVX-01: The upcoming three-year data for EVX-01 is anticipated to provide critical insights into T-cell responses and potential for broader applications in high mutational burden cancers.

This summary encapsulates Evaxion's financial performance, strategic initiatives, future outlook, and challenges faced, providing a comprehensive overview of the company's current standing and future direction.